Veru Inc. Share Price & Technical Analysis
VERU · $2.35 (+5.86%)
Healthcare / Biotechnology
$2.35
+5.86%
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosar…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
5% return in May, -19% avg return in past 3 year May month.
10% return in 2026, -70% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 14% | 4% | -12% | 0% | 5% | – | – | – | – | – | – | – | 10% |
| 25 | -15% | -5% | -6% | -5% | -7% | 14% | -19% | -33% | 19% | -25% | -17% | -16% | -116% |
| 24 | -34% | 22% | 17% | 88% | -27% | -18% | 12% | -11% | -5% | 0% | -8% | -8% | 28% |
| 23 | 8% | -31% | -70% | 9% | -23% | 19% | 9% | -16% | -32% | 25% | 3% | -22% | -120% |
| 22 | -12% | 5% | -14% | 142% | 2% | -12% | 7% | 28% | -24% | 5% | -55% | -5% | 66% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$36.07M
P/E ratio
—
52W high
$7.40
52W low
$2.05
Volume
89,864
Beta
-1.17
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Veru Inc. share price today?
- Veru Inc. (VERU) last traded around $2.35 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does VERU have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VERU. Download the app for real-time alerts.
- How can I analyze Veru Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.